Zelira in the news
For media related enquiries please contact Damien Carbon at Profile Media
Ph: +61 (0) 412 332 122 E: email@example.com
Zelira Therapeutics (ASX:ZLD) launches Zenivol in Australia
Zelira Therapeutics (ZLD) proprietary cannabinoid medicine, Zenivol, can now be prescribed to patients in Australia.
This comes after the company received the Therapeutic Goods Administration’s (TGA) Special Access Scheme approval for the treatment.